Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers

Prolongation of the QT interval is clinically important because it may be associated with torsade de pointes, a potentially fatal arrhythmia. The objective of this study was to define the effects on electrocardiogram (ECG) of intravenous conivaptan, the first arginine vasopressin V1A/V2-receptor ant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in therapy 2007-03, Vol.24 (2), p.310-318
Hauptverfasser: Lasseter, Kenneth C, Dilzer, Stacy C, Smith, Neila
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 318
container_issue 2
container_start_page 310
container_title Advances in therapy
container_volume 24
creator Lasseter, Kenneth C
Dilzer, Stacy C
Smith, Neila
description Prolongation of the QT interval is clinically important because it may be associated with torsade de pointes, a potentially fatal arrhythmia. The objective of this study was to define the effects on electrocardiogram (ECG) of intravenous conivaptan, the first arginine vasopressin V1A/V2-receptor antagonist indicated for the treatment of euvolemic hyponatremia, on hospitalized patients without congestive heart failure. After a placebo run-in period, participants in this randomized, single-blind, placebo- and positive-controlled, parallel-group study received an intravenous 20-mg loading dose of conivaptan (day 1), followed by a 40-mg/d continuous infusion (days 1-4); a 20-mg loading dose of conivaptan (day 1), followed by an 80-mg/d continuous infusion (days 1-4); or moxifloxacin 400 mg (positive control) or placebo from day 1 to day 4. The primary ECG endpoint was QTc interval duration, which was determined by the individually corrected QT interval for each subset; secondary endpoints included QT intervals corrected with Bazett's formula and Fridericia's formula. No clinically notable changes in ECG parameters were associated with conivaptan, suggesting that conivaptan did not affect cardiac repolarization or cardiac conduction.
doi_str_mv 10.1007/BF02849899
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF02849899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17565921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c285t-f2871e1a0f6c51c0f1218754a343bc5349ef358b91fe7d526c4bee8b75eab2c33</originalsourceid><addsrcrecordid>eNpFkF1LwzAUhoMobk5v_AGSa6Gaj6ZJvdPhdDAQYYJ3JU1PbKVrStIW9u-NbLCLw4GX530vHoRuKXmghMjHlxVhKs1Vnp-hOVWZSOKxczQnMqUJ4-p7hq5C-CWEESnUJZpRKTKRMzpHYd0NXk_QuTFg47pm0v2guycM1oIZAnYdHmrAn1uDm24AP-kW667CLqYeQxsh74z2VeN-vO7rxuBee72DyIZYwTXodqj3eHLtGAdieo0urG4D3Bz_An2tXrfL92Tz8bZePm8Sw5QYEsuUpEA1sZkR1BBLGVVSpJqnvDSCpzlYLlSZUwuyEiwzaQmgSilAl8xwvkD3h13jXQgebNH7Zqf9vqCk-DdXnMxF-O4A92O5g-qEHlXxPy5Ra5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Lasseter, Kenneth C ; Dilzer, Stacy C ; Smith, Neila</creator><creatorcontrib>Lasseter, Kenneth C ; Dilzer, Stacy C ; Smith, Neila</creatorcontrib><description>Prolongation of the QT interval is clinically important because it may be associated with torsade de pointes, a potentially fatal arrhythmia. The objective of this study was to define the effects on electrocardiogram (ECG) of intravenous conivaptan, the first arginine vasopressin V1A/V2-receptor antagonist indicated for the treatment of euvolemic hyponatremia, on hospitalized patients without congestive heart failure. After a placebo run-in period, participants in this randomized, single-blind, placebo- and positive-controlled, parallel-group study received an intravenous 20-mg loading dose of conivaptan (day 1), followed by a 40-mg/d continuous infusion (days 1-4); a 20-mg loading dose of conivaptan (day 1), followed by an 80-mg/d continuous infusion (days 1-4); or moxifloxacin 400 mg (positive control) or placebo from day 1 to day 4. The primary ECG endpoint was QTc interval duration, which was determined by the individually corrected QT interval for each subset; secondary endpoints included QT intervals corrected with Bazett's formula and Fridericia's formula. No clinically notable changes in ECG parameters were associated with conivaptan, suggesting that conivaptan did not affect cardiac repolarization or cardiac conduction.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/BF02849899</identifier><identifier>PMID: 17565921</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Antidiuretic Hormone Receptor Antagonists ; Benzazepines - administration &amp; dosage ; Benzazepines - adverse effects ; Dose-Response Relationship, Drug ; Electrocardiography ; Female ; Heart Conduction System - drug effects ; Humans ; Injections, Intravenous ; Male ; Single-Blind Method</subject><ispartof>Advances in therapy, 2007-03, Vol.24 (2), p.310-318</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c285t-f2871e1a0f6c51c0f1218754a343bc5349ef358b91fe7d526c4bee8b75eab2c33</citedby><cites>FETCH-LOGICAL-c285t-f2871e1a0f6c51c0f1218754a343bc5349ef358b91fe7d526c4bee8b75eab2c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17565921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lasseter, Kenneth C</creatorcontrib><creatorcontrib>Dilzer, Stacy C</creatorcontrib><creatorcontrib>Smith, Neila</creatorcontrib><title>Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><description>Prolongation of the QT interval is clinically important because it may be associated with torsade de pointes, a potentially fatal arrhythmia. The objective of this study was to define the effects on electrocardiogram (ECG) of intravenous conivaptan, the first arginine vasopressin V1A/V2-receptor antagonist indicated for the treatment of euvolemic hyponatremia, on hospitalized patients without congestive heart failure. After a placebo run-in period, participants in this randomized, single-blind, placebo- and positive-controlled, parallel-group study received an intravenous 20-mg loading dose of conivaptan (day 1), followed by a 40-mg/d continuous infusion (days 1-4); a 20-mg loading dose of conivaptan (day 1), followed by an 80-mg/d continuous infusion (days 1-4); or moxifloxacin 400 mg (positive control) or placebo from day 1 to day 4. The primary ECG endpoint was QTc interval duration, which was determined by the individually corrected QT interval for each subset; secondary endpoints included QT intervals corrected with Bazett's formula and Fridericia's formula. No clinically notable changes in ECG parameters were associated with conivaptan, suggesting that conivaptan did not affect cardiac repolarization or cardiac conduction.</description><subject>Adult</subject><subject>Antidiuretic Hormone Receptor Antagonists</subject><subject>Benzazepines - administration &amp; dosage</subject><subject>Benzazepines - adverse effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Heart Conduction System - drug effects</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Single-Blind Method</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkF1LwzAUhoMobk5v_AGSa6Gaj6ZJvdPhdDAQYYJ3JU1PbKVrStIW9u-NbLCLw4GX530vHoRuKXmghMjHlxVhKs1Vnp-hOVWZSOKxczQnMqUJ4-p7hq5C-CWEESnUJZpRKTKRMzpHYd0NXk_QuTFg47pm0v2guycM1oIZAnYdHmrAn1uDm24AP-kW667CLqYeQxsh74z2VeN-vO7rxuBee72DyIZYwTXodqj3eHLtGAdieo0urG4D3Bz_An2tXrfL92Tz8bZePm8Sw5QYEsuUpEA1sZkR1BBLGVVSpJqnvDSCpzlYLlSZUwuyEiwzaQmgSilAl8xwvkD3h13jXQgebNH7Zqf9vqCk-DdXnMxF-O4A92O5g-qEHlXxPy5Ra5w</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>Lasseter, Kenneth C</creator><creator>Dilzer, Stacy C</creator><creator>Smith, Neila</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20070301</creationdate><title>Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers</title><author>Lasseter, Kenneth C ; Dilzer, Stacy C ; Smith, Neila</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c285t-f2871e1a0f6c51c0f1218754a343bc5349ef358b91fe7d526c4bee8b75eab2c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Antidiuretic Hormone Receptor Antagonists</topic><topic>Benzazepines - administration &amp; dosage</topic><topic>Benzazepines - adverse effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Heart Conduction System - drug effects</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Single-Blind Method</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lasseter, Kenneth C</creatorcontrib><creatorcontrib>Dilzer, Stacy C</creatorcontrib><creatorcontrib>Smith, Neila</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lasseter, Kenneth C</au><au>Dilzer, Stacy C</au><au>Smith, Neila</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers</atitle><jtitle>Advances in therapy</jtitle><addtitle>Adv Ther</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>24</volume><issue>2</issue><spage>310</spage><epage>318</epage><pages>310-318</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Prolongation of the QT interval is clinically important because it may be associated with torsade de pointes, a potentially fatal arrhythmia. The objective of this study was to define the effects on electrocardiogram (ECG) of intravenous conivaptan, the first arginine vasopressin V1A/V2-receptor antagonist indicated for the treatment of euvolemic hyponatremia, on hospitalized patients without congestive heart failure. After a placebo run-in period, participants in this randomized, single-blind, placebo- and positive-controlled, parallel-group study received an intravenous 20-mg loading dose of conivaptan (day 1), followed by a 40-mg/d continuous infusion (days 1-4); a 20-mg loading dose of conivaptan (day 1), followed by an 80-mg/d continuous infusion (days 1-4); or moxifloxacin 400 mg (positive control) or placebo from day 1 to day 4. The primary ECG endpoint was QTc interval duration, which was determined by the individually corrected QT interval for each subset; secondary endpoints included QT intervals corrected with Bazett's formula and Fridericia's formula. No clinically notable changes in ECG parameters were associated with conivaptan, suggesting that conivaptan did not affect cardiac repolarization or cardiac conduction.</abstract><cop>United States</cop><pmid>17565921</pmid><doi>10.1007/BF02849899</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0741-238X
ispartof Advances in therapy, 2007-03, Vol.24 (2), p.310-318
issn 0741-238X
1865-8652
language eng
recordid cdi_crossref_primary_10_1007_BF02849899
source MEDLINE; SpringerLink Journals
subjects Adult
Antidiuretic Hormone Receptor Antagonists
Benzazepines - administration & dosage
Benzazepines - adverse effects
Dose-Response Relationship, Drug
Electrocardiography
Female
Heart Conduction System - drug effects
Humans
Injections, Intravenous
Male
Single-Blind Method
title Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A05%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20conivaptan:%20effects%20on%20the%20QTc%20interval%20and%20other%20electrocardiographic%20parameters%20in%20healthy%20volunteers&rft.jtitle=Advances%20in%20therapy&rft.au=Lasseter,%20Kenneth%20C&rft.date=2007-03-01&rft.volume=24&rft.issue=2&rft.spage=310&rft.epage=318&rft.pages=310-318&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/BF02849899&rft_dat=%3Cpubmed_cross%3E17565921%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17565921&rfr_iscdi=true